Internal mammary node failure in invasive breast cancer patients who received post-operative radiotherapy without prophylactic internal mammary node irradiation.

IF 2.9
Yasushi Hamamoto, Kenji Makita, Kei Nagasaki, Hiromitsu Kanzaki, Mariko Kochi, Michiko Yamashita, Mina Takahashi, Daisuke Takabatake, Kenjiro Aogi
{"title":"Internal mammary node failure in invasive breast cancer patients who received post-operative radiotherapy without prophylactic internal mammary node irradiation.","authors":"Yasushi Hamamoto, Kenji Makita, Kei Nagasaki, Hiromitsu Kanzaki, Mariko Kochi, Michiko Yamashita, Mina Takahashi, Daisuke Takabatake, Kenjiro Aogi","doi":"10.1007/s12282-025-01746-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) patients who would benefit the most from prophylactic internal mammary node (IMN) irradiation have not been clearly identified. Risk factors for ipsilateral IMN failure in BC patients who received post-operative radiotherapy (PORT) without prophylactic IMN irradiation were investigated.</p><p><strong>Methods: </strong>Between January 2012 and March 2013, unilateral invasive BC patients who had no clinically positive IMN and received PORT without prophylactic IMN irradiation after breast-conserving surgery or mastectomy were retrospectively reviewed. At that time, prophylactic IMN irradiation was not recommended for clinically negative IMN by Japanese BC guidelines. To identify risk factors of IMN failure, the following factors were assessed using univariate and multivariate analyses: primary tumor location, hormone receptor status, human epidermal growth factor receptor 2 (HER2), axillary node status, and administration of neoadjuvant chemotherapy (NAC).</p><p><strong>Results: </strong>A total of 194 BC patients (median age, 53 years; pStage I, 92; pStage II, 57; pStage III, 17; received NAC, 28) were analyzed. Median follow-up time with CT and/or FDG-PET/CT was 110 months (range, 4-132 months). IMN failure-free rates were 99% at 5 year and 98% at 10 year. The 10-year overall survival rate was 93%. In multivariate analysis, hormone receptor negativity was the only significant unfavorable factor for IMN failure (Hazard ratio 20.389, [95% CI 1.601-259.610], p = 0.02).</p><p><strong>Conclusions: </strong>Hormone receptor status may have a greater impact on IMN failure compared to the primary tumor location and axillary lymph node status in the modern systemic therapy era. Because our study was a small retrospective study, further large-scale studies are needed.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast cancer (Tokyo, Japan)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12282-025-01746-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Breast cancer (BC) patients who would benefit the most from prophylactic internal mammary node (IMN) irradiation have not been clearly identified. Risk factors for ipsilateral IMN failure in BC patients who received post-operative radiotherapy (PORT) without prophylactic IMN irradiation were investigated.

Methods: Between January 2012 and March 2013, unilateral invasive BC patients who had no clinically positive IMN and received PORT without prophylactic IMN irradiation after breast-conserving surgery or mastectomy were retrospectively reviewed. At that time, prophylactic IMN irradiation was not recommended for clinically negative IMN by Japanese BC guidelines. To identify risk factors of IMN failure, the following factors were assessed using univariate and multivariate analyses: primary tumor location, hormone receptor status, human epidermal growth factor receptor 2 (HER2), axillary node status, and administration of neoadjuvant chemotherapy (NAC).

Results: A total of 194 BC patients (median age, 53 years; pStage I, 92; pStage II, 57; pStage III, 17; received NAC, 28) were analyzed. Median follow-up time with CT and/or FDG-PET/CT was 110 months (range, 4-132 months). IMN failure-free rates were 99% at 5 year and 98% at 10 year. The 10-year overall survival rate was 93%. In multivariate analysis, hormone receptor negativity was the only significant unfavorable factor for IMN failure (Hazard ratio 20.389, [95% CI 1.601-259.610], p = 0.02).

Conclusions: Hormone receptor status may have a greater impact on IMN failure compared to the primary tumor location and axillary lymph node status in the modern systemic therapy era. Because our study was a small retrospective study, further large-scale studies are needed.

浸润性乳腺癌术后放疗未进行预防性内乳淋巴结照射的患者内乳淋巴结衰竭。
背景:乳腺癌(BC)患者谁将从预防性乳腺内淋巴结(IMN)照射中获益最大尚未明确确定。对接受术后放疗(PORT)而不进行预防性IMN放疗的BC患者同侧IMN失败的危险因素进行了研究。方法:回顾性分析2012年1月至2013年3月期间,保乳手术或乳房切除术后无临床IMN阳性且接受PORT治疗且未进行预防性IMN照射的单侧浸润性BC患者。当时,日本BC指南不推荐对临床阴性的IMN进行预防性IMN照射。为了确定IMN失败的危险因素,使用单因素和多因素分析评估以下因素:原发肿瘤位置、激素受体状态、人表皮生长因子受体2 (HER2)、腋窝淋巴结状态和新辅助化疗(NAC)的使用。结果:共194例BC患者(中位年龄53岁;第一阶段,92岁;第二阶段,57岁;第三阶段,17人;接受NAC治疗,28例)。CT和/或FDG-PET/CT的中位随访时间为110个月(范围4-132个月)。5年和10年IMN无失败率分别为99%和98%。10年总生存率为93%。在多因素分析中,激素受体阴性是IMN失败的唯一显著不利因素(风险比20.389,[95% CI 1.601-259.610], p = 0.02)。结论:在现代全身治疗时代,激素受体状态可能比原发肿瘤位置和腋窝淋巴结状态对IMN失败的影响更大。由于我们的研究是一项小型回顾性研究,需要进一步的大规模研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信